semaglutide launch date The upcoming expiry of the patent in India in mid-March 2026 is Post-patent Semaglutide Launch Race Begins

This flat-rate pricing model eliminates the financial anxiety of dose escalation

The additive effect validates the biological hypothesis: amylin and GLP-1 engage overlapping but distinct neural circuits, and activating both produces a synergistic response that neither achieves independently

Today, federal GLP-1 multidistrict litigation involving gastrointestinal injuries now includes thousands of pending cases, and a separate federal multidistrict litigation has been established for vision-loss claims involving non-arteritic anterior ischemic optic neuropathy (NAION)

LQ: data curation, formal analysis, project administration, and writingreview and editing

Heerspink, H

One moment youre diligently following your personalized weight loss and health plan, feeling empowered by the progress youre making, and the next, an unexpected illness like a bacterial infection strikes